What's the dosing schedule for Skyrizi?

After your initial starter doses, you'll receive Skyrizi as a subcutaneous (under the skin) maintenance dose every 12 weeks (4 times per year) to treat either plaque psoriasis or psoriatic arthritis, or every 8 weeks (6 times per year) for Crohn's disease or ulcerative colitis.

You can self-administer maintenance injections into your thigh or stomach area at home after proper training from your healthcare provider. Your healthcare provider will tell you your exact dose to use.

Plaque psoriasis and psoriatic arthritis

For the treatment of plaque psoriasis and psoriatic arthritis in adults, you’ll receive your first two starter subcutaneous (injected under the skin) doses of Skyrizi 4 weeks apart, then you’ll have an injection every 12 weeks thereafter. It is given from a prefilled pen or prefilled syringe.

• If you are being treated for psoriatic arthritis, your may receive Skyrizi alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs), such as methotrexate.
• Once you start your Skyrizi maintenance injections, you’ll have only 4 doses per year.
• You may self-administer these injections after proper training from your healthcare provider.

Crohn's disease

For treatment of Crohn's disease in adults, the dosing schedule is 3 intravenous (given into a vein) starter doses given 4 weeks apart (at Week 0, 4 and 8), then a subcutaneous (under the skin) injection given at Week 12, followed by a subcutaneous injection every 8 weeks thereafter.

• After completing the initial starter doses, you may receive Skyrizi as an injection under the skin (subcutaneous) using the prefilled cartridge with an on-body injector (OBI) or by a prefilled syringe.
• You can administer this at home after training from your healthcare provider. The injection OBI dose is delivered in about 5 minutes and you will not see the needle.

Ulcerative colitis

For treatment of moderately to severely active ulcerative colitis in adults:

• The dosing schedule is 3 intravenous (given into a vein) starter doses given 4 weeks apart (at Week 0, 4 and 8), then a subcutaneous (under the skin) injection given at Week 12, followed by an injection every 8 weeks thereafter.
• Following the induction period, Skyrizi treatment can be maintained at home using an on-body injector (OBI) or by a prefilled syringe. The OBI injection dose is delivered in about 5 minutes and you will not see the needle.

Before use, you should receive training on how to inject the medicine. Be sure to read the instructions for use before you start using Skyrizi and each time you get a refill. There may be new information you need to know. If you do not have the instructions, ask your pharmacist for a copy. Use this medicine exactly as directed by your doctor.

Related questions

• What does psoriasis look like?
• How do you get psoriasis and is it contagious?
• How does Tremfya work to treat plaque and psoriatic arthritis?

Can I use Skyrizi at home?

Yes, for treatment of plaque psoriasis and psoriatic arthritis you can inject Skyrizi subcutaneously (under the skin) into your thigh or stomach area (abdomen) using a prefilled syringe or a pen injector, after training from your healthcare provider. You may also receive these injections at your doctor’s office if you prefer.

For Crohn's disease and ulcerative colitis, the initial starter doses are given intravenously (into a vein) in a clinic. Then you will receive Skyrizi as an injection under the skin (subcutaneously) using the prefilled cartridge with an on-body injector or as a prefilled syringe. You can administer subcutaneous doses at home after training from your healthcare provider.

What is the typical dose of Skyrizi?

The recommended starter and maintenance dose of Skyrizi (risankizumab) for both plaque psoriasis and psoriatic arthritis is 150 mg given as a subcutaneous (under the skin) injection. ​

The recommended starter doses of Skyrizi for treatment of Crohn's disease is 600 mg administered by intravenous infusion over at least one hour for the first three doses (Week 0, 4, and 8). Then, the recommended maintenance dosage is 180 mg or 360 mg given by subcutaneous (under the skin) injection at Week 12, and then every 8 weeks, thereafter.

The recommended starter doses of Skyrizi for treatment of ulcerative colitis is 1,200 mg administered by intravenous infusion over at least two hours for the first three doses (Week 0, 4, and 8). Then, the recommended maintenance dosage is 180 mg or 360 mg given by subcutaneous (under the skin) injection at Week 12, and then every 8 weeks, thereafter.

If a dose is missed, administer the dose as soon as possible, then resume dosing at the regularly scheduled time. If you inject too much Skyrizi, call your doctor right away for instructions.

Only use the dose of Skyrizi that your doctor prescribes.

This is not all the information you need to know about Skyrizi (risankizumab-rzaa) for safe and effective use and does not take the place of your healthcare provider's directions. Review the product information and discuss this information and any questions you have with your doctor or other health care provider.